Principal Display Panel (100 mg Capsule Bottle)
Lyrica
Product Images NDC 54868-6063
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 20 technical images submitted to the FDA as part of the official labeling for Lyrica (NDC 54868-6063). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Physicians Total Care, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Principal Display Panel (150 mg Capsule Bottle)
Principal Display Panel (200 mg Capsule Bottle)
This is a prescription drug label for Lyrich 26646 4P G, with an NDC number of 54868-6063-1. It was distributed by Physicians Total Care and is a 400 mg extended-release tablet. However, there seems to be some inaccurate and incomplete information in the text.*
Principal Display Panel (25 mg Capsule Bottle)
Principal Display Panel (50 mg Capsule Bottle)
Principal Display Panel (75 mg Capsule Bottle)
The text is a logo or a phrase that reads "PHYSICIANS,| TOTAL CARE". A description cannot be generated based on this text alone.*
Figure (Lyrica 01)
This is a medical formula to calculate the creatinine clearance rate for female patients. It involves subtracting the age of the patient from 140, multiplying the result by the patient's weight in kilograms, and multiplying that result by the serum creatinine level in mg/dL. The output is then divided by 72 and multiplied by 0.85 for female patients.*
Chemical Structure (Lyrica 02)
Figure 1 (Lyrica 03)
Figure 2 (Lyrica 04)
Figure 3 (Lyrica 05)
Figure 4 (Lyrica 06)
Figure 5 (Lyrica 07)
This text appears to be a chart or table displaying the percentage of improvement in pain from baseline for patients who received different treatments, including Pregatalin 100 mg three times a day, Pregabalin 0 mg three times a day, and Placeta. However, the characters in the text are garbled and unreadable, making it difficult to provide a more complete description.*
Figure 6 (Lyrica 08)
Figure 7 (Lyrica 09)
Figure 8 (Lyrica 10)
Figure 9 (Lyrica 11)
Figure 10 (Lyrica 12)
Figure 11 (Lyrica 13)
The data shows the percentage of subjects who experienced improvement after taking Pregabalin compared to Placebo. The percentage of subjects who experienced improvement was 100%. Graphical data is also available for reference.*
Logo (Lyrica 14)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
